

## Selectin Ligands: Synthesis of 3'-*O*-Sialyl-6'-*O*-Sulfo Lewis<sup>a</sup>, NeuAc $\alpha$ 2 $\rightarrow$ 3(6-*O*-SO<sub>3</sub>Na)Gal $\beta$ 1 $\rightarrow$ 3 (Fuc $\alpha$ 1 $\rightarrow$ 4) GlcNAc $\beta$ -OMe

Rakesh Vig, Rakesh K. Jain, Conrad F. Piskorz and Khushi L. Matta\*

Department of Gynecologic Oncology, Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY 14263, USA

The stereoselective synthesis of 3'-*O*-sialyl-6'-*O*-sulfo-Le<sup>a</sup>, a stereoisomer of the major capping group of GLYCAM-I is described.

L-Selectin is a membrane bound lectin which mediates the initial attachment of lymphocytes to the high endothelial venules (HEV) of lymph nodes.<sup>1</sup> It functions in leukocyte trafficking, thrombosis and inflammation. GLYCAM-I and CD<sub>34</sub>, two HEV associated selectin ligands, are mucin-like *O*-linked glycoproteins with carbohydrate chains<sup>2,3</sup> containing fucose, sialic acid and sulfate. Selectins recognize carbohydrate ligands comprised of these elements, such as, the sialyl Le<sup>x</sup>, sialyl Le<sup>a</sup>, sulfated Le<sup>a</sup> and sulfated Le<sup>x</sup> structures.<sup>4</sup> In a previous paper we described the chemical synthesis of 3'-*O*-sialyl-6'-*O*-sulfo Le<sup>x</sup>- $\beta$ -OMe,<sup>5</sup> the carbohydrate moiety which has been reported to be a major capping group of GLYCAM-I.<sup>6</sup> Thus, in a continuing effort to shed more light on the ligand specificities of L-selectin, we describe herein the synthesis of the title compound. Our purpose is to determine what effect an alteration in the position of interglycosidic linkages will have on selectin binding.

Compounds **1** and **2** (Fig. 1) were prepared from key intermediates (**3–6**)<sup>7</sup> by stereoselective transformation, as described in Schemes 1 and 2, respectively. Reaction of the easily accessible 6-*O*-pivaloyl derivative **6** with bromide **3** (Scheme 1) in benzene–nitromethane (1:1, *v/v*) at 55 °C afforded **7** in 80% yield.  $\alpha$ -L-Fucopyranosylation of **7** by **4** under CuBr<sub>2</sub>–Bu<sub>4</sub>NBr<sup>8</sup> followed by selective removal of the *O*-acetyl group furnished the appropriately protected trisaccharide **9** in 67% yield. It is noteworthy that the 6-*O*-pivaloyl group remains intact. Isopropylideneation of **9** according to Catelani's procedure<sup>9</sup> afforded the 3,4-*O*-isopropylidene derivative **10** in 70% yield. Chloroacetylation<sup>10</sup> of **10** and removal of iso-

propylidene afforded the triol derivative **11** in 60% yield. Condensation of the sialic acid donor **5**<sup>7c</sup> with **11** under *N*-iodosuccinimide–triflic acid<sup>11</sup> conditions at –70 °C<sup>5</sup> provided **12** in 67% yield. Removal of the chloroacetyl group gave compound **13** in 76% yield. The selective sulfation of **13** with SO<sub>3</sub>–pyridine complex at 5 °C provided the 6-*O*-sulfo compound which, after removal of *O*-benzyl (10% Pd–C), and the *O*-acetyl group (MeOH–MeONa), addition of water to hydrolyse the ester, afforded the target compound **1**.

The synthesis of the trisaccharide **2** involved the selective removal of the *O*-acetyl group of **15** followed by isopropylideneation to give compound **16**. The synthesis of **21** from **17**






Fig. 1 Sulfated Sialyl Le<sup>a</sup> **1** and Sulfated Sialyl Lacto-*N*-biose **2** target molecules and key intermediates (**3–6**) involved in their synthesis



**Scheme 1** Reagents and conditions: i, **3** (1.5 equiv.), **6** (1.0 equiv.), Hg(CN)<sub>2</sub> (1.5 equiv.), benzene–nitromethane 1:1 (*v/v*), 55 °C, 16 h, 80%; ii, **7** (1.0 equiv.), **4** (2.0 equiv.), CuBr<sub>2</sub>, (3.0 equiv.), Bu<sub>4</sub>NBr (3.0 equiv.), ClCH<sub>2</sub>CH<sub>2</sub>Cl–DMF 5:1 (*v/v*), 4 Å molecular sieves, 16 h; iii, MeOH–MeONa, 16 h, 67%; iv, 0.15% camphorsulfonic acid, DMP, 20 °C, 24 h, MeOH–H<sub>2</sub>O 10:1 (*v/v*), 100 °C, 6 h, 70%; v, chloroacetic anhydride (1.2 equiv.), NaHCO<sub>3</sub> (5 equiv.), DMF, –30 °C, 3 h, 60% aq. AcOH, 70 °C, 3 h, 60%; vi, **5** (3 equiv.), *N*-iodosuccinimide–triflic acid (3 equiv.), propionitrile, –75 °C, 3 h 67%; vii, thiourea (5 equiv.), 2,6-lutidine (2.5 equiv.), EtOH–CH<sub>2</sub>Cl<sub>2</sub> 1:1 (*v/v*), 80 °C, 3 h, 76%; viii, SO<sub>3</sub>–pyridine complex–DMF (1.5 equiv.), 5 °C, 4 h; ix, MeOH, 10% Pd–C, 24 h, MeOH–MeONa, 24 h, H<sub>2</sub>O, 4 h, Na<sup>+</sup> resin, 50% from **13**

was achieved by a reaction sequence similar to that described for the preparation of **14** from **10**. The formation of **22** from its methyl ester **21** was achieved by a lithium iodide–pyridine<sup>12</sup> procedure. Further treatment of **22** with hydrazine hydrate in ethanol at 80 °C followed by *N*-acetylation with excess acetic anhydride in methanol–dichloromethane and removal of the *O*-acetyl group with MeOH–MeONa provided compound **2** in 14% yield from **21**. The structures of **1** and **2** were confirmed by NMR and FAB MS.† The synthesis of Le<sup>a</sup> type derivatives are convenient and economical as compared to the corresponding Le<sup>x</sup> structures.

In a collaborative study with Dr Varki *et al.* a series of compounds were examined for binding properties with E-, L- and P-Selectins in an ELISA competition assay where relative inhibitory concentrations (RIC) were determined against that of NeuAc $\alpha$ 2 $\rightarrow$ 3Gal $\beta$ 1 $\rightarrow$ 4(Fuc $\alpha$ 1 $\rightarrow$ 3)GlcNAc and 3-*O*-SO<sub>3</sub>Na-Gal $\beta$ 1 $\rightarrow$ 4(Fuc $\alpha$ 1 $\rightarrow$ 3)GlcNAc [unpublished data].



**Scheme 2** Reagents and conditions: i, CH<sub>2</sub>Cl<sub>2</sub>–MeOH 1 : 1 (v/v)–MeONa, 0.15% camphorsulfonic acid, DMP, 24 h, MeOH–H<sub>2</sub>O 10 : 1 (v/v), 100 °C, 6 h, 60%; ii, chloroacetic anhydride (1.2 equiv.), NaHCO<sub>3</sub> (5 equiv.), DMF, –30 °C, 3 h; iii, 60% aq. AcOH, 70 °C, 3 h, 54%; iv, **5** (3 equiv.), *N*-iodosuccinimide–triflic acid (3 equiv.), propionitrile, –45 °C, 2 h, 59%; v, thiourea (5 equiv.), 2,6-lutidine (2.5 equiv.), EtOH–CH<sub>2</sub>Cl<sub>2</sub> 1 : 1 (v/v), 80 °C, 3 h, 77%; vi, SO<sub>3</sub>–pyridine complex–DMF (1.5 equiv.), 5 °C, 4 h; vii, LiI, (8 equiv.), pyridine, 120 °C, 3 h; viii, MeOH–hydrazine hydrate (5 : 1, v/v), 80 °C, 6 h, Ac<sub>2</sub>O (excess), MeOH–CH<sub>2</sub>Cl<sub>2</sub> 1 : 1, 0 °C, 1 h; ix, MeOH–MeONa, 48 h, Na<sup>+</sup> resin, 14% from **22**. Phth = phthalimido group.

We thank Robert D. Locke for his help in preparing this manuscript. These investigations<sup>13</sup> were supported by Grant No. CA35329 awarded by the National Cancer Institute.

Received, 14th July 1995, Com. 5/02945G

### Footnote

† Selected NMR data for **1**: <sup>1</sup>H NMR (D<sub>2</sub>O, 400 MHz) δ 5.05 (d, *J* 4 Hz, H-1<sup>''</sup>), 4.56 (d, *J* 7.8 Hz, H-1'), 3.52 (s, OMe), 2.79 (dd, *J* 4.5 Hz, H-3<sup>'''</sup> e), 2.06 and 2.05 (each s, 2 × NAc), 1.79 (t, *J* 12.2 Hz, H-3<sup>'''</sup> a), 1.19 (d, *J* 6.5 Hz, H-6<sup>''</sup>); <sup>13</sup>C NMR (D<sub>2</sub>O, 100.6 MHz) δ 101.59 (C-1'), 100.82 (C-1), 98.35 (C-2<sup>''</sup>), 97.11 (C-1<sup>''</sup>), 75.29 (C-3), 74.49 (C-3'), 74.45 (C-4), 66.98 (C-6'), 61.35 (C-9<sup>'''</sup>), 58.69 (C-6), 56.07 (OMe), 14.35 (C-6<sup>''</sup>), FABMS *m/z* 959.6 [M + H]<sup>+</sup>.

For **2**: <sup>1</sup>H NMR (D<sub>2</sub>O, 400 MHz) δ 4.86 (d, *J* 8.1 Hz, H-1), 4.60 (d, *J* 8.6 Hz, H-1'), 2.76 (dd, *J* 4.5 Hz, H-1<sup>''</sup> e), 2.05 and 1.94 (each s, 2 × NAc), 1.79 (t, *J* 12.2 Hz, H-3<sup>''</sup> a); <sup>13</sup>C NMR (D<sub>2</sub>O, 100.6 MHz) δ 102.47 (C-1'), 98.77 (C-2<sup>''</sup>), 98.71 (C-1), 82.12 (C-3'), 74.38 (C-3), 66.58 (C-6'), 61.46 (C-9<sup>''</sup>), 59.74 (C-6).

### References

- A. Varki, *Proc. Natl. Acad. Sci. USA*, 1994, **91**, 7390; L. A. Lasky, *Science*, 1992, **258**, 964; M. P. Bevilacqua and R. M. Nelson, *J. Clin. Invest.*, 1993, **91**, 379; W. M. Gallatin, I. L. Weismann and E. C. Butcher, *Nature*, 1983, **303**, 30.
- S. Hemmerich, C. R. Bertozzi, H. Leffler and S. D. Rosen, *Biochemistry*, 1994, **33**, 4820; Y. Imai, M. S. Singer, C. Fennie, L. A. Lasky and S. D. Rosen, *J. Cell Biol.*, 1991, **113**, 1213; L. A. Lasky, M. S. Singer, D. Dowbenko, Y. Imai, W. I. Henzel, C. Grimley, C. Fennie, N. Gillett, S. R. Watson and S. D. Rosen, *Cell*, 1992, **69**, 927; S. Baumhueter, M. S. Singer, W. Henzel, S. Hemmerich, M. Renz, S. D. Rosen and L. A. Lasky, *Science*, 1993, **262**, 436.
- Y. Imai, L. A. Lasky and S. D. Rosen, *Nature*, 1993, **361**, 555.
- E. V. Chandrasekaran, R. K. Jain and K. L. Matta, *J. Biol. Chem.*, 1992, **267**, 23806; K. L. Matta, C. F. Piskorz, G. V. Reddy, E. V. Chandrasekaran and R. K. Jain, *ACS Symposium*, Series 560, ed. P. Kovac, 1994, 120.
- R. K. Jain, R. Vig, R. Rampal, E. V. Chandrasekaran and K. L. Matta, *J. Am. Chem. Soc.*, 1994, **116**, 12123.
- S. Hemmerich and S. D. Rosen, *Biochemistry*, 1994, **33**, 4830.
- (a) S. Sato, Y. Ito, T. Nukada, Y. Nakahara and T. Ogawa, *Carbohydr. Res.*, 1987, **167**, 197; (b) R. K. Jain and K. L. Matta, *Carbohydr. Res.*, 1990, **208**, 51; (c) S. Marra and P. Sinay, *Carbohydr. Res.*, 1989, **187**, 35.
- S. Sato, M. Mori, Y. Ito and T. Ogawa, *Carbohydr. Res.*, 1986, **187**, C6.
- G. Catelani, F. Colonna and A. Marra, *Carbohydr. Res.*, 1988, **182**, 297.
- G. J. F. Chittenden and H. Regelling, *Recl. Trav. Chim. Pays-Bas*, 1987, **106**, 44.
- P. Konradsson, D. R. Mootoo, R. E. McDevitt and B. Fraser-Reid, *J. Chem. Soc., Chem. Commun.*, 1990, 270.
- K. C. Nicolaou, C. W. Hummel and Y. Iwabuchi, *J. Am. Chem. Soc.*, 1992, **114**, 3126.
- This publication is part 103 of Synthetic Studies in Carbohydrates. For part 102, see R. K. Jain, C. F. Piskorz and K. L. Matta, *Bioorg. & Med. Chem. Letters*, 1995, **5**, 1389.